Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 316 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

BRIEF COMMUNICATION Table of Contents   
Year : 2015  |  Volume : 26  |  Issue : 2  |  Page : 297-301
Non-tolerability of double-filtration plasmapheresis in antibody-incompatible kidney transplant candidates


1 Department of Nephrology, Dialysis and Organ Transplantation, CHU, Kremlin Bicêtre, Paris, France
2 Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, France
3 Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil; INSERM U1043, IFR-BMT, CHU Purpan Toulouse, France
4 Department of Nephrology, Dialysis and Organ Transplantation, CHU, Kremlin BicÍtre, Paris; INSERM U1014, CHU Kremlin BicÍtre, France
5 Department of Nephrology, Dialysis and Organ Transplantation; INSERM U1014, CHU Kremlin Bicêtre, France

Correspondence Address:
Prof. Nassim Kamar
Department of Nephrology, Dialysis, and Organ Transplantation, CHU Rangueil, 1 avenue Jean Poulhès, TSA 50032, 31059 Toulouse Cedex 9
France
Login to access the Email id


DOI: 10.4103/1319-2442.152435

PMID: 25758878

Rights and Permissions

Few studies have reported the use of double-filtration plasmapheresis (DFPP) in antibody-incompatible kidney transplantation. To assess the efficiency and tolerability of DFPP, we prospectively studied four chronic hemodialysis patients from two centers undergoing antibody-incompatible kidney transplantation. DFPP was used for ABO-incompatible transplantation (n = 1), for high human leukocyte antigen (HLA) immunization levels (n = 2) or for the presence of a donor-specific antibody (DSA) against a potential living donor (n = 1). In all the patients, the DFPP program was discontinued because of the adverse effects. Low blood pressure occurred during the first hour of the session in all the patients. A significant loss of plasma proteins, clotting factors and immunoglobulins also occurred during this treatment. In addition, fistula thrombosis was diagnosed in two patients. Three patients experienced gastrointestinal symptoms. The DFPP reduced the titers of the anti-B antibodies and reduced the levels of DSA in one patient, but had no effect on anti-HLA antibodies in the remaining two patients. Our study highlights the non-tolerability and poor efficacy of DFPP prior to antibody-incompatible kidney transplantation that limit its extensive use in the desensitization protocols.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3317    
    Printed29    
    Emailed0    
    PDF Downloaded422    
    Comments [Add]    

Recommend this journal